Aller au contenu
Radio Logo

BioSpace

BioSpace
Dernier épisode

285 épisodes

  • BioSpace

    The untapped potential of drug repurposing

    19/11/2026 | 19 min
    In this episode of Denatured, I speak with Daniel Tillett, CEO of Racura Oncology and Sten Sörensen, CEO of Cereno Scientific. We explore why the FDA is now prioritizing drug repurposing, and what it will take to turn existing molecules into viable new therapies.
    Host
    Jennifer C. Smith-Parker, Director of Insights, BioSpace
    Guests
    Daniel Tillett, CEO, Racura Oncology
    Sten Sörensen, CEO, Cereno Scientific
    Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
  • BioSpace

    Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight

    18/11/2026 | 22 min
    The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech history; ObesityWeek and Clinical Trials on Alzheimer’s Disease conferences in full swing.
  • BioSpace

    Can we finally get ahead of drug shortages?

    12/11/2026 | 20 min
    In this episode of Denatured, you'll hear from Christina Smolke, co-founder & CEO at Antheia and Kyle Pudenz, senior vice president and head of data & AI product at Cencora. We explore why drug shortages are getting worse, and how combining predictive supply-chain analytics with agile, distributed manufacturing could finally make essential medicines more resilient and accessible.
    Host
    Jennifer C. Smith-Parker, Director of Insights, BioSpace
    Guests
    Christina Smolke, Co-founder & CEO, Antheia
    Kyle Pudenz, Senior Vice President, Head of Data & AI Product, Cencora
    Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
  • BioSpace

    Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November

    11/11/2026 | 23 min
    Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about the risk of a rare eye condition that can lead to vision loss; and the agency is set to decide on no fewer than 11 therapies this month, including closely watched applications from Summit Therapeutics, Vertex and Capricor Therapeutics.
  • BioSpace

    Beyond the needle: The future of intratumoral therapy

    05/11/2026 | 21 min
    In this episode of Denatured, you’ll hear from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratumoral therapies trigger systemic anti-cancer immunity from a local injection, and redefine a foundational platform in immuno-oncology.
    Host
    Jennifer C. Smith-Parker, Director of Insights, BioSpace
    Guests
    Lewis Bender, President & CEO, Intensity Therapeutics
    Paul-Peter Tak, President, CEO and Board Director, Candel Therapeutics
    Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Plus de podcasts Science de la vie
À propos de BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Site web du podcast

Écoutez BioSpace, Speaking of Psychology ou d'autres podcasts du monde entier - avec l'app de radio.fr

Obtenez l’app radio.fr
 gratuite

  • Ajout de radios et podcasts en favoris
  • Diffusion via Wi-Fi ou Bluetooth
  • Carplay & Android Auto compatibles
  • Et encore plus de fonctionnalités